clinical trial · NCT03482752
Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar ProteinosisMolgramostim
brief summary
SAV006-03 is an open-label extension study for participants who had completed the IMPALA study. At the baseline visit, eligible participants may continue or re-start treatment with 300 µg inhaled molgramostim (recombinant human Granulocyte-Macrophage Colony Stimulating Factor; GM-CSF) administered intermittently in cycles of seven days molgramostim, administered once daily, and seven days off treatment. Participants will be treated with inhaled molgramostim for up to 36 months. During the trial, whole lung lavage will be applied as rescue therapy.
started
Apr 16, 2018
primary completion
Jan 14, 2021
completion
Jan 14, 2021
last updated
Jul 3, 2024
official title
An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol